In conclusion, as outlined in Figure 8B, our study has uncovered a novel signalling pathway involving TPα/TPβ and both PRK1 and PRK2, providing a mechanism for how agonist activation of the TP may exacerbate prostate cancer, including CRPC. Here, PKN1 is linked to prostate carcinoma.